Thyrocare Board Approves Dividend, Auditor, Director Appointments & Subsidiary Investment
Thyrocare's Board recommended a final dividend of ₹7.00 per share for FY26, totaling ₹9.33 per share. Price Waterhouse Chartered Accountants LLP appointed as statutory auditors for five years. Rahul Franklin Guha re-appointed as CMD & CEO for five years. Investment up to ₹5.50 crore approved for subsidiary Think Health Diagnostics.
The dividend recommendation, auditor appointment, management re-appointments, and subsidiary investment are material events that can impact investor perception and company operations.
The announcement includes a positive development regarding the recommendation of a final dividend and key appointments to leadership and audit roles, alongside a strategic investment in a subsidiary.
Thyrocare Technologies Limited announced the outcome of its Board Meeting held on May 07, 2026. The Board recommended a final dividend of ₹7.00 per equity share for FY2025-26, subject to shareholder approval at the ensuing AGM. This, along with the interim dividend of ₹7.00 per equity share (post-bonus adjusted to ₹2.33), brings the total dividend for FY2025-26 to ₹9.33 per equity share.
The Board also approved the appointment of M/s. Price Waterhouse Chartered Accountants LLP as Statutory Auditors for a five-year term from the conclusion of the 26th AGM (2026) until the 31st AGM (2031), subject to shareholder approval. M/s. Jitender Navneet & Co. were appointed as Cost Auditors for FY2026-27.
Key management and director changes were approved: Mr. Rahul Franklin Guha was re-appointed as Chairman, Managing Director & CEO for five years from May 4, 2027, to May 3, 2032. Mr. Uday Patel Kadam and Mr. Gaurav Verma were appointed as Additional Directors (Non-Executive, Non-Independent) effective May 8, 2026. The Board also noted the resignations of Mr. Dharmil Nirupam Sheth and Dr. Dhaval Rajesh Shah as Non-Executive, Non-Independent Directors, both effective May 07, 2026.
Furthermore, the Board approved an investment of up to ₹5.50 crore in the equity shares of Think Health Diagnostics Private Limited, a wholly-owned subsidiary, to support its operations and capital expenditure. The Memorandum of Association (MOA) of the company was also approved for alteration to align with the Companies Act, 2013, and broaden its scope within the healthcare and diagnostics ecosystem.
The Board Meeting commenced at 3:35 PM and concluded at 5:40 PM on May 07, 2026.
What to do with a filing like this
Thyrocare Technologies Limited filed this with the NSE as a statutory disclosure, categorised under dividend. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Thyrocare Technologies Limited. Read the original for the full detail.